99.17
0.96%
-0.96
After Hours:
99.74
0.57
+0.57%
Novartis Ag Adr stock is traded at $99.17, with a volume of 945.01K.
It is down -0.96% in the last 24 hours and down -6.15% over the past month.
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$100.13
Open:
$99.8
24h Volume:
945.01K
Relative Volume:
0.84
Market Cap:
$200.19B
Revenue:
$49.94B
Net Income/Loss:
$17.60B
P/E Ratio:
26.66
EPS:
3.72
Net Cash Flow:
$12.51B
1W Performance:
-2.62%
1M Performance:
-6.15%
6M Performance:
-5.11%
1Y Performance:
+1.94%
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
99.17 | 200.19B | 49.94B | 17.60B | 12.51B | 8.53 |
LLY
Lilly Eli Co
|
796.03 | 711.48B | 40.86B | 8.37B | -2.28B | 9.25 |
NVO
Novo Nordisk Adr
|
111.70 | 485.07B | 39.36B | 13.79B | 9.83B | 3.086 |
JNJ
Johnson Johnson
|
146.63 | 359.29B | 87.70B | 14.68B | 19.03B | 6.05 |
ABBV
Abbvie Inc
|
174.33 | 310.43B | 55.53B | 5.12B | 15.62B | 2.88 |
MRK
Merck Co Inc
|
99.76 | 255.49B | 63.17B | 12.15B | 14.84B | 4.77 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
Jan-16-24 | Resumed | UBS | Buy |
Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
Dec-05-22 | Upgrade | Stifel | Hold → Buy |
Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jan-10-22 | Resumed | Citigroup | Buy |
Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-22-21 | Initiated | Bernstein | Mkt Perform |
Mar-10-21 | Downgrade | Argus | Buy → Hold |
Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Buy |
Sep-10-20 | Upgrade | UBS | Neutral → Buy |
Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
Dec-11-18 | Resumed | Jefferies | Buy |
Oct-09-18 | Initiated | Guggenheim | Neutral |
Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Jan-25-18 | Reiterated | Leerink Partners | Outperform |
Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer - GlobeNewswire Inc.
Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.
5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart
5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar
Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart
Addressing unmet needs for inherited neuromuscular diseases - Novartis
Weekly Upgrades and Downgrades - InvestorPlace
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Canada Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
MEDIA STATEMENTNovartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™ - Barchart
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis at ASH - Novartis
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook - Yahoo Finance
Novartis 2022 Financial Results - Novartis
Novartis Financial Results – Q2 2023 - Novartis
Translational medicine research at Novartis - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Collaborations - Novartis
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart
Germany Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
21 Best Healthcare Companies to Invest In - Morningstar
The UAE Antifungal Drugs Market Size & Outlook, 2030 - Grand View Research
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):